Onconetix Announces Reverse Stock Split

Authorized common shares will remain at 250,000,000 despite the reduction in outstanding shares.

Rhea-AI Summary

Onconetix (Nasdaq: ONCO) announced board approval of a 1-for-10 reverse stock split, expected to take effect on November 6, 2026.

The expected effective time is 12:01 a.m. Eastern Time. Outstanding common shares will fall from approximately 5,886,774 as of October 21, 2026, to approximately 588,677, before fractional-share adjustments. Shareholders will receive cash instead of fractional shares. Ownership percentages will otherwise remain unchanged, as will common shareholders’ rights and privileges. Proportionate adjustments will apply, under their respective terms, to exercise or conversion prices and shares issuable under outstanding options, warrants, convertible securities and equity incentive plans.

News Explained

The reverse split leaves Onconetix’s 250 million authorized common shares unchanged even as outstanding shares fall, so it reduces the outstanding count but not the company’s authorized-share ceiling.

Argus 15 min delay 25 alerts

-21.82% vs previous close $0.31 last price 1.4x rel. volume Open Argus

Details

Market move: ONCO -21.82% vs previous close. 1-for-10 reverse stock split

-30.3% Trough in 28 min

$0.27 – $0.46 Day Range

$1.64M Mkt Cap at Last Price

On Oct 26, the day this news came out, the latest delayed price for ONCO is 21.82% below the previous close. Argus tracked a trough of -30.3% from its starting point during tracking. Our momentum scanner has recorded 25 alerts for this stock so far that day. The latest delayed price is $0.31.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Reverse split ratio: 1-for-10 Effective date: November 6, 2026 at 12:01 a.m. Eastern Time Outstanding shares before split: Approximately 5,886,774 shares +2 more

Reverse split ratio

1-for-10

Approved by the Board

Effective date

November 6, 2026 at 12:01 a.m. Eastern Time

Expected effective time

Outstanding shares before split

Approximately 5,886,774 shares

As of October 21, 2026

Outstanding shares after split

Approximately 588,677 shares

Before adjustments for fractional shares

Authorized common shares

250,000,000 shares

Unchanged by the reverse split

Previous Stock split Reports

3 past events · Latest: May 19

Same Type 3 events

1. May 19

   Reverse split

   24h Move

   -61.6%

   Announced a 1-for-10 reverse split, reducing outstanding shares from about 11.4 million to 1.14 million.

2. Mar 23

   Reverse split

   24h Move

   -3.0%

   Announced a 1-for-5 reverse split, reducing outstanding shares from about 3.6 million to 0.7 million.

3. Jun 11

   Reverse split

   24h Move

   -15.9%

   Announced a 1-for-85 reverse split after stockholder approval, reducing shares to approximately 521,863.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cusip, par value, convertible securities

3 terms

cusip technical

"assigned a new CUSIP number, 68237Q500, in connection with the reverse stock split"

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

View in glossary

par value financial

"the par value of the Company’s common stock, which will remain at $0.00001 per share"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

convertible securities financial

"outstanding options, warrants, convertible securities and equity incentive plans"

Convertible securities are bonds or preferred shares that can be exchanged for a company’s common stock at a predetermined price or under specified conditions. They matter because they combine the steadiness of a loan or fixed dividend with the potential upside of ownership; like a safety‑net that carries a one‑time ticket to become a shareholder, they affect expected returns and can dilute existing stock if converted.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CINCINNATI, Ohio, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”), today announced that its Board of Directors has approved a one-for-ten (1-for-10) reverse stock split of the Company’s outstanding common stock. The reverse split is expected to become effective at 12:01 a.m. Eastern Time on November 6, 2026. The Company’s common stock has been assigned a new CUSIP number, 68237Q500, in connection with the reverse stock split.

Following the reverse split, every ten (10) shares of Onconetix common stock will be automatically exchanged into one share of common stock. The Company’s common stock will continue to trade on Nasdaq under the symbol “ONCO”.

The reverse split will reduce the number of outstanding shares of common stock from approximately 5,886,774 shares outstanding as of October 21, 2026 to approximately 588,677 shares, before giving effect to adjustments resulting from the treatment of fractional shares. The reverse stock split will not change the number of authorized shares of common stock, which will remain at 250,000,000 shares, or the par value of the Company’s common stock, which will remain at $0.00001 per share. No fractional shares will be issued in connection with the reverse split. Stockholders who would otherwise be entitled to receive fractional shares will instead receive cash payments in lieu of such fractional shares.

The reverse stock split will be effected simultaneously for all outstanding shares of the Company’s common stock and will affect all of the Company’s stockholders uniformly. The reverse stock split will not affect any stockholder’s percentage ownership interest in the Company, except to the extent that a stockholder would otherwise be entitled to receive a fractional share for which cash will be paid in lieu thereof. The reverse stock split will not affect the par value of the Company’s common stock and will also not affect the number of authorized shares or par value of our preferred stock. The rights and privileges of the holders of the common stock will be unaffected by the reverse stock split. Proportionate adjustments will be made, as applicable and in accordance with their respective terms, to the exercise or conversion prices and the number of shares issuable under the Company’s outstanding options, warrants, convertible securities and equity incentive plans.

About Onconetix, Inc.

Onconetix, Inc. (Nasdaq: ONCO) is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative oncology solutions. Onconetix owns Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union under the IVDR, which it anticipates will be marketed in the U.S. as a lab developed test through its license agreement with Labcorp. For more information, visit www.onconetix.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Onconetix’s current expectations and actual results could differ materially. Investors should read the risk factors set forth in Onconetix’s Annual Report on Form 10-K filed with the SEC on March 13, 2026, and periodic reports filed with the SEC on or after the date thereof. All forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof. Onconetix does not undertake an obligation to update or revise any forward-looking statement except as required by applicable law.

Investor and Media Contact:

Onconetix, Inc.

201 E. Fifth Street, Suite 1900

Cincinnati, OH 45202

Phone: (513) 620-4101

Email: investors@onconetix.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Onconetix’s reverse stock split take effect, and what is the ratio?

Onconetix’s 1-for-10 reverse stock split is expected to become effective at 12:01 a.m. Eastern Time on November 6, 2026. Every ten common shares will automatically be exchanged for one common share.

Will Onconetix’s reverse stock split change its authorized shares?

Onconetix’s authorized common shares will remain at 250,000,000, and common stock par value will remain at $0.00001 per share. The reverse split will also leave the number of authorized preferred shares and their par value unchanged.